Bupropion's (Zyban(®) SR) effectiveness to treat symptoms experienced in marihuana withdrawal was tested in a double-blind, placebo-controlled study with chronic, heavy marihuana users. Participants maintained their usual marihuana intake until Quit Day after which they were required to cease intake of THC products for 14 days. A Withdrawal Discomfort Score revealed that for 7 days immediately following cessation, placebo-treated subjects reported more symptoms than bupropion-treated subjects. Self-reported craving for marihuana increased for the placebo-treated group but not for those treated with bupropion. Measures of sleep and cognitive performance were not different between the two groups. Participants in the bupropion treatment arm were more likely to complete the study than those randomized to the placebo arm (50% completion for bupropion vs. 33% completion for placebo). These results suggest that bupropion may be useful for alleviating marihuana withdrawal symptoms and be useful in subject retention during long-term cessation programs.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411526 | PMC |
| http://dx.doi.org/10.4137/SART.S9706 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
New insight in psychotic cannabis withdrawal: case series and brief overview.
Riv Psichiatr
December 2024
San Luigi Gonzaga Hospital, University of Turin, Orbassano (Torino), Italy - Department of Neurosciences "Rita Levi Montalcini", University of Turin, Italy.
Background: Cannabis is the most used recreational drug worldwide. Its use can increase the risk of developing psychotic disorders and exacerbate their course. However, little is known about the relationship between psychosis and withdrawal and the literature is still scarce.
View Article and Find Full Text PDFPsychosis associated with cannabis withdrawal: systematic review and case series.
Br J Psychiatry
December 2024
Department of Psychiatry, University of Oxford, UK.
Article Synopsis
- Abruptly stopping heavy cannabis use can lead to withdrawal symptoms like irritability, anxiety, insomnia, and in some cases, trigger acute psychosis.
- A systematic review and a comprehensive analysis of psychiatric records identified a total of 112 individuals whose first episodes of psychosis were linked to cannabis withdrawal.
- Continued cannabis use after experiencing a psychotic episode significantly increases the risk of relapse compared to individuals who choose to abstain.
Does Cannabis Legalization Endanger Children and Adolescents? The Cannabis Act (CanG) came into force on April 1, 2024. It regulates the "controlled supply of cannabis to adults for recreational purposes". In the USA, legalization has contributed to a decrease in the risk perception of the health hazards of consumption and an increase in risky consumption patterns, including among adolescents.
View Article and Find Full Text PDFAge of tobacco, nicotine and cannabis use initiation in Switzerland: a sequence analysis among adolescents and young adults.
BMC Public Health
November 2024
Department of Epidemiology and Health Systems, Research Group on Adolescent Health, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.
Background: To explore at what age youth start using tobacco and/or nicotine products, which product is used first, product initiation sequences, and whether some socio-demographic characteristics are associated with substance use initiation.
Methods: Data were collected from an online questionnaire disseminated through social media and professional partners, targeting youth aged 14-25 in French-speaking Switzerland in August 2022. The final sample included 1362 participants.
A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats.
Neuropsychopharmacology
November 2024
Lambert Initiative for Cannabinoid Therapeutics, The University of Sydney, Sydney, NSW, Australia.
Medicinal cannabis is being used worldwide and there is increasing use of novel cannabis products in the community. Cannabis contains the major cannabinoids, Δ-tetrahydrocannabinol (Δ-THC) and cannabidiol (CBD), but also an array of minor cannabinoids that have undergone much less pharmacological characterization. Cannabinol (CBN) is a minor cannabinoid used in the community in "isolate' products and is claimed to have pro-sleep effects comparable to conventional sleep medications.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!